Literature DB >> 9189143

Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease.

K Ishii1, M Sasaki, H Kitagaki, S Yamaji, S Sakamoto, K Matsuda, E Mori.   

Abstract

UNLABELLED: Although regional cerebral metabolism and blood flow in Alzheimer's disease (AD) have been studied extensively with PET and SPECT, few reports have been concerned with cerebellar metabolism or perfusion in Alzheimer's disease. To evaluate cerebellar glucose metabolism in Alzheimer's disease patients, we studied the cerebellar and cerebral metabolic rate for glucose (CMRglc) using 2[18F]fluoro-2-deoxy-D-glucose (18F-FDG) and PET.
METHODS: Sixty-eight patients with Alzheimer's disease and 13 age-matched normal control subjects were examined. According to scores obtained on the Mini-Mental State Examination (MMSE), Alzheimer's disease patients were classified into three groups: severe (n = 9), moderate (n = 33) and mild (n = 26).
RESULTS: The cerebellar glucose metabolism in the severe Alzheimer's disease group was significantly lower (cerebellar glucose metabolism: 5.71 +/- 0.62 mg/100 g/min) than that of the control group (6.85 +/- 0.66 mg/100 g/min), while temporal and parietal CMRglc were much more decreased. The cerebellar glucose metabolism in the mild and moderate Alzheimer's disease groups also showed lower levels than that of the control group, but the differences did not reach significant levels. Like other cortical CMRglc, the cerebellar glucose metabolism correlated with cognitive impairments.
CONCLUSION: In severe Alzheimer's disease, cerebellar glucose metabolism is significantly reduced. The method of analysis using normalization of regional metabolic data to cerebellar values may be liable to err in severe Alzheimer's disease patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9189143

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  54 in total

1.  Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence.

Authors:  Jia Yao; Ryan T Hamilton; Enrique Cadenas; Roberta Diaz Brinton
Journal:  Biochim Biophys Acta       Date:  2010-06-09

2.  Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis.

Authors:  Marzia Perluigi; Rukhsana Sultana; Giovanna Cenini; Fabio Di Domenico; Maurizio Memo; William M Pierce; Raffaella Coccia; D Allan Butterfield
Journal:  Proteomics Clin Appl       Date:  2009-06-01       Impact factor: 3.494

3.  Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies.

Authors:  Kazunari Ishii; Hiroki Sasaki; Atsushi K Kono; Naokazu Miyamoto; Tetsuya Fukuda; Etsuro Mori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-31       Impact factor: 9.236

4.  Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease.

Authors:  Lisa Mosconi; Wai H Tsui; Henry Rusinek; Susan De Santi; Yi Li; Gene-Jack Wang; Alberto Pupi; Joanna Fowler; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-04       Impact factor: 9.236

5.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

6.  Detectability of hypometabolic regions in mild Alzheimer disease: function of time after the injection of 2-[fluorine 18]-fluoro-2-deoxy-D-glucose.

Authors:  Setsu Sakamoto; Kazunari Ishii; Kayo Hosaka; Tetsuya Mori; Masahiro Sasaki; Etsuro Mori
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

7.  Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease.

Authors:  Jia Yao; Ronald W Irwin; Liqin Zhao; Jon Nilsen; Ryan T Hamilton; Roberta Diaz Brinton
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

8.  Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies.

Authors:  Tomonori Kanda; Kazunari Ishii; Takafumi Uemura; Naokazu Miyamoto; Toshiki Yoshikawa; Atsushi K Kono; Etsuro Mori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-26       Impact factor: 9.236

Review 9.  Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.

Authors:  Jia Yao; Roberta Diaz Brinton
Journal:  Adv Pharmacol       Date:  2012

Review 10.  The role of novel chitin-like polysaccharides in Alzheimer disease.

Authors:  Rudy J Castellani; George Perry; Mark A Smith
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.